The Genetics of 5ASA Induced Nephrotoxicity
Help is required to identify patients for this study investigating the genetics of 5ASA induced nephrotoxicity. This is the first of what we hope will be a series of genetic studies, led by the UK IBD Genetics consortium, investigating rare adverse drug events. The study had been adopted as an NIHR portfolio study (renal & gastro) and is funded by the Serious Adverse Events Forum.
Our aim is to recruit 200 UK patients and a further 100 international patients over the next 2 years. Although this is a very rare side effect the Drug Induced Liver Injury group have demonstrated that it can be done! Using the NIHR infrastructure we need to establish as many research sites across the UK as possible to facilitate case identification and recruitment. Most of the paperwork relating to site set up can be done from our research office.
National Registry of eosinophilic oesophagitis
Eosinophilic Oesophagitis Registry - The Oesophageal section of the British Society of Gastroenterology has set up a National Registry of eosinophilic oesophagitis, to determine the frequency of this condition in Britain, to study its epidemiology and to encourage research into its patho-physiology and treatment. As you know, eosinophilic oesophagitis is being increasingly recognised in recent years and presents with food bolus obstruction, dysphagia and heartburn in adults, and regurgitation, food refusal and abdominal pain in children. Endoscopic changes have been described but the diagnosis is a histological one, based on eosinophilic infiltration of the oesophageal mucosa, > 15 or 20 per high power field, more than is normally found in gastro-oesophageal reflux disease.
We suspect eosinophilic oesophagitis may be under-diagnosed. We have put up a notice regarding the setting up of this Registry on the BSG website, and are also e-mailing members of the Pathological Society of Great Britain and Ireland and ENT UK. We would also like to draw your attention to this condition, to remind you to refer patients who present with dysphagia, food impaction and atypical or resistant reflux symptoms for endoscopy and oesophageal biopsies even if the oesophageal mucosa appears macroscopically normal. We would also ask that you enter all cases of eosinophilic oesophagitis into the Registry.
Data may be entered without the need for a log-in.
One of the priorities of the CSSC is improving access to treatment for patients with acute and chronic GI problems arising from cancer treatments. I would be most grateful if you would complete a short questionnaire on your local service to establish the current service provision in the UK.
The link below will take you to the survey in addition to links to BSG Guidance on the management of GI problems arising as a result of treatment for cancer and to a Resource Pack prepared by Lesley Smith, Consequences of Treatment Project Manager, DH National Cancer Survivorship Initiative.
- Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer
- Resource Pack
Hyperplastic Polyposis Study
Hyperplastic polyps are common and are generally thought to have no role in the development of colorectal cancer. Hyperplastic polyposis, on the other hand, is recognised by the World Health Organisation as a disease and is thought to be associated with a significant risk of colorectal cancer.
Idiosyncratic Drug-induced Liver Injury Study
Formerly: Hepatic Adverse Drug Reactions Study
The international Drug-induced Liver Injury Consortium (iDILIC), a multi-national research group led jointly by Professor Ann Daly, Newcastle University and Dr Guruprasad Aithal, Nottingham Digestive Diseases Centre: NIHR Biomedical Research Unit is studying the genetic susceptibility to idiosyncratic drug-induced liver injury. The UK arm of the study, DILIGEN, is a portfolio study adopted by Comprehensive Local Research Networks (CLRN) nationally.
Family Gastric Cancer Study
The Familial Gastric Cancer Study aims to identify new gastric cancer predisposing genes and to improve the treatment and management of individuals with an inherited predisposition to gastric cancer.